Cargando…
Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors
IMPORTANCE: In science and medical research, extreme and dichotomous conclusions may be drawn based on whether the P value falls above or below the threshold. The fragility index (ie, the minimum number of changes from nonevents to events resulting in loss of statistical significance) captures the v...
Autores principales: | Bomze, David, Asher, Nethanel, Hasan Ali, Omar, Flatz, Lukas, Azoulay, Daniel, Markel, Gal, Meirson, Tomer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584930/ https://www.ncbi.nlm.nih.gov/pubmed/33095247 http://dx.doi.org/10.1001/jamanetworkopen.2020.17675 |
Ejemplares similares
-
Systemic review of the robustness of randomized controlled trials for the treatment of cholangiocarcinoma in three domains: survival-inferred fragility index, restricted mean survival time, and the spin effect
por: Horesh, Nir, et al.
Publicado: (2022) -
Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation
por: Meirson, Tomer, et al.
Publicado: (2020) -
Immunotherapy Discontinuation in Metastatic Melanoma: Lessons from Real-Life Clinical Experience
por: Asher, Nethanel, et al.
Publicado: (2021) -
Systemic structural analysis of alterations reveals a common structural basis of driver mutations in cancer
por: Meirson, Tomer, et al.
Publicado: (2023) -
Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma
por: Meirson, Tomer, et al.
Publicado: (2022)